Vacancy expired!
The Head of the Multiple Sclerosis & Neurorepair Research Unit (RU) will serve as the single point of accountability for Research in this area, reporting to the SVP, Head of Research. (S)he will have the following core accountabilities:
#LI-SK1
PhD or MD/PhD in a life science field
A significant proportion of all multiple sclerosis patients benefit from treatment with one of the drugs in Biogen’s extensive MS Portfolio. These – together with other excellent products that target neuroinflammation and the relapsing-remitting phase of the disease – have completely changed the prognosis for newly diagnosed patients. Nevertheless, MS has not been cured and, in particular, the disability associated with long-term progression is not satisfactorily addressed by any existing medication. The goal of Biogen is to fill this and other gaps by continued innovation in the MS space. Focusing on neuronal and glial protection, as well as axonal survival and regeneration, this strategy should also generate leads for other areas of Neuroscience where a need for CNS repair has been identified.